Similar articles

• Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.

  te Boekhorst PA, Löwenberg B, Sonneveld P. te Boekhorst PA, et al. Leukemia. 1994 Sep;8(9):1480-6. Leukemia. 1994. PMID: 7522289
• Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

  Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS. Avramis VI, et al. Cancer Chemother Pharmacol. 1989;24(4):203-10. doi: 10.1007/BF00257619. Cancer Chemother Pharmacol. 1989. PMID: 2473850
• Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.

  Fazlina N, Maha A, Jamal R, Zarina AL, Cheong SK, Hamidah H, Ainoon O, Zulkifli SZ, Hamidah NH. Fazlina N, et al. Hematology. 2007 Feb;12(1):33-7. doi: 10.1080/10245330600940030. Hematology. 2007. PMID: 17364990
• Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.

  Capizzi RL, White JC, Powell BL, Perrino F. Capizzi RL, et al. Semin Hematol. 1991 Jul;28(3 Suppl 4):54-69. Semin Hematol. 1991. PMID: 1780754 Review.
• [Application of bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody for the analysis of tumor cell kinetics by flow cytometry].

  Kanno M, Takeda Y, Nakamura S. Kanno M, et al. Nihon Rinsho. 1992 Oct;50(10):2333-7. Nihon Rinsho. 1992. PMID: 1280304 Review. Japanese.